Does NAD+ Boost Energy? What the Evidence Says (and GLP-1 Fatigue)

NAD+ (nicotinamide adenine dinucleotide) is one of the most discussed supplements in the longevity and biohacker world, and clinics now charge $200–$500 a session for intravenous NAD+ drips marketed to “restore cellular energy.” The biology is compelling: NAD+ is genuinely central to mitochondrial energy metabolism and declines with age^[1]. But compelling biology does not guarantee a compelling pill. This article separates what the human trial evidence actually shows from what is extrapolated from mice, cell studies, and marketing. The honest answer is that oral NAD+ precursors (NMN, NR) do raise NAD+ in blood and muscle, but human RCTs have not reliably shown improved subjective energy, stamina, or fatigue scores in healthy or overweight adults^[3][8]. IV NAD+ has no controlled energy-outcome trials at all. There is also a question many GLP-1 users are asking: does NAD+ help with the fatigue that often comes during rapid weight loss on Ozempic, Wegovy, or Zepbound? The honest evidence-based answer is covered below — and it is not the answer supplement sellers want you to hear.

What NAD+ actually does in energy metabolism

NAD+ is a coenzyme found in every cell. It acts as an electron carrier in the mitochondrial electron transport chain — the process that converts food into ATP, the cell’s energy currency. Without adequate NAD+, mitochondria cannot run the oxidative phosphorylation reactions that power muscle contraction, organ function, and cognition (Verdin 2015^[1]). NAD+ also activates sirtuins (a class of proteins linked to longevity signaling) and PARPs (DNA-repair enzymes), so it sits at the intersection of energy, repair, and aging biology. The foundational insight is real and Nobel-adjacent: Otto Warburg’s work on NAD+ in metabolism dates to the 1930s.

The problem is the leap from “NAD+ is essential for mitochondria” to “taking a supplement will make your mitochondria run faster and make you feel more energetic.” Cells regulate NAD+ levels tightly and make NAD+ from multiple dietary sources — tryptophan, niacin, and the newer precursors NMN and NR. Whether oral supplementation raises NAD+ meaningfully above baseline in humans, in which tissues, and whether that elevation translates to any perceptible energy benefit are empirical questions that require human trials (Rajman 2018^[2]).

NAD+ precursors in the human body: what the preclinical story says

In animal models, NAD+ precursors — especially NMN and NR — have produced impressive results: older mice on NMN run farther, have better muscle function, improved insulin sensitivity, and show signs of mitochondrial rejuvenation. A 2018 review of in-vivo NAD+ precursor studies across mouse models found benefits in muscle, liver, heart, kidney, and neural tissue, summarizing a strong preclinical case for therapeutic potential (Rajman 2018^[2]). These rodent data generated enormous enthusiasm and drove a wave of human trials.

The human evidence on energy and fatigue: what RCTs actually show

The first rigorous human trial of NR, published in 2018, recruited 24 healthy middle-aged and older adults in a randomized, double-blind, crossover design (Martens 2018^[3]). Participants took 500 mg NR twice daily (1,000 mg/day) or placebo for six weeks, then crossed over. The headline finding: NR was well tolerated and substantially raised whole-blood NAD+ metabolites — by roughly 60% above placebo. This confirmed that oral NR reaches the systemic circulation and raises NAD+. What the study did not find: meaningful improvements in resting metabolic rate, blood pressure, sympathetic nerve activity, or other cardiovascular parameters. Subjective energy and fatigue were not primary outcomes. The precursor works pharmacokinetically; clinical benefit was not demonstrated.

A companion question is what NR does in human skeletal muscle — the tissue where mitochondrial energy production matters most for perceived fatigue and exercise capacity. Elhassan and colleagues (2019^[5]) gave 1,000 mg/day NR to aged adults for 12 weeks in a randomized controlled study and found it augmented the NAD+ metabolome in skeletal muscle and induced gene expression changes including anti-inflammatory signatures. Importantly, muscle NAD+ levels did rise — but the trial was not powered or designed to detect improvements in subjective energy, fatigue, or muscle strength as primary outcomes, so it cannot tell us whether the biochemical signal translates to clinical benefit.

On the side of a positive, if modest, functional signal: a 2020 double-blind crossover study by Dolopikou and colleagues gave acute NR (500 mg single dose) to older individuals and found improved exercise performance markers and reduced oxidative stress compared with placebo (Dolopikou 2020^[6]). This is a small, acute-dose study, and it supports the idea that NR may have genuine exercise-related effects in older adults who may have lower baseline NAD+. It is the strongest human functional finding available — and it is still a single, small study of a single dose, not a chronic fatigue trial.

For NMN, the cleanest human RCT comes from Yoshino and colleagues (2021^[7]), who gave 250 mg/day NMN or placebo to postmenopausal women with prediabetes for 10 weeks. NMN significantly improved skeletal muscle insulin sensitivity — a metabolically important finding — but did not produce changes in body weight, body composition, or, crucially, measures of subjective energy or fatigue. The authors did not claim an energy benefit; the paper focused squarely on insulin signaling. That is a real metabolic effect from NMN, but it is not the same as feeling more energetic.

Also in 2018, Dollerup and colleagues randomized obese men to NR (2,000 mg/day) or placebo for 12 weeks in a rigorously designed trial (Dollerup 2018^[4]). NR raised NAD+ metabolites but did not improve insulin sensitivity, lipid profiles, or body composition relative to placebo. Neither subjective energy nor fatigue was improved. A high dose of NR, in people with exactly the metabolic profile where one might expect benefit, moved the biomarker and nothing else.

The 2025 systematic review and meta-analysis by Prokopidis and colleagues specifically examined NMN and NR effects on skeletal muscle mass and function across all available human RCTs (Prokopidis 2025^[8]). The overall finding was mixed: some trials showed modest benefits in specific muscle function parameters (particularly in older or sarcopenic individuals), while others showed no effect. The authors concluded that evidence was insufficient to recommend NMN or NR supplementation for muscle-function improvement in the general population. Crucially, subjective energy and fatigue outcomes were not sufficiently measured across trials to support any conclusion about them.

IV NAD+ drips: zero controlled energy-outcome trials

If the oral precursor evidence is thin for energy outcomes, the IV NAD+ evidence is essentially nonexistent. Intravenous NAD+ bypasses gut absorption and delivers NAD+ directly into the bloodstream at far higher transient concentrations than any oral dose. Clinics charge hundreds of dollars per session on the premise that this “floods cells with NAD+” and produces immediate energy and mental clarity. There is not a single peer-reviewed, placebo-controlled RCT evaluating energy, fatigue, cognitive function, or physical performance as an outcome of IV NAD+ infusion in a healthy adult population. The clinical literature on IV NAD+ is largely limited to addiction-medicine case series and observational work. People report feeling a flush or sense of activation during infusion, which is physiologically plausible (NAD+ infusion transiently activates multiple receptors), but this is not the same as a controlled demonstration of an energy benefit over placebo.

GLP-1 fatigue: what is actually causing it, and what actually helps

Many people starting Ozempic (semaglutide), Wegovy, Mounjaro, or Zepbound (tirzepatide) report fatigue — especially in the first weeks or at dose escalation. This is one of the most common reasons patients search for “NAD+ for energy on GLP-1.” Understanding why GLP-1 fatigue occurs is essential to knowing what actually helps. See our full mechanistic guide at GLP-1 fatigue: causes and management; the short version is this:

• Calorie deficit is the primary driver. GLP-1 drugs suppress appetite dramatically, often cutting daily intake by several hundred to over a thousand calories. A large, rapid calorie deficit causes tiredness in anyone — the body downregulates non-essential activity when it perceives energy scarcity. This is physiology, not a drug toxicity.
• Reduced carbohydrate and glycogen stores. When caloric intake falls sharply, muscle glycogen depletes faster, which directly impairs exercise tolerance and contributes to that “heavy legs” and low-energy feeling.
• Nausea and vomiting reduce electrolyte intake. Nausea — the most common GLP-1 side effect — can reduce fluid and electrolyte intake, producing subclinical dehydration and deficiencies in sodium, potassium, and magnesium that all contribute to fatigue.
• Protein intake may be insufficient. When appetite is suppressed globally, protein intake often falls disproportionately. Inadequate protein impairs muscle protein synthesis, recovery, and can worsen fatigue.

Evidence-based management of GLP-1 fatigue centers on correcting those root causes: maintaining adequate protein (commonly recommended at 1.2–1.6 g/kg of body weight per day during active weight loss), ensuring hydration with electrolytes (particularly sodium, potassium, magnesium), eating consistent small meals around the drug’s nausea window, and pairing the medication with resistance training to preserve lean mass. These are the interventions that address the actual mechanisms. None of the published human NAD+ trials have enrolled GLP-1 users, and no study has tested whether NMN, NR, or IV NAD+ reduces fatigue in that population. Recommending NAD+ for GLP-1 fatigue is an extrapolation without any direct evidence base. The clinics selling IV NAD+ drips to Wegovy patients are billing a plausible story against zero trial data in that context. For more on understanding NAD+ supplementation, see our overview at our NAD+ guide.

The honest verdict

The NAD+ energy story is a case of compelling mechanistic biology outrunning the clinical evidence. Here is the honest summary of where the science stands:

• The biology is real. NAD+ is genuinely essential for mitochondrial energy production, and NAD+ declines with age (Verdin 2015^[1]; Rajman 2018^[2]). This is not contested.
• Oral precursors raise NAD+ — consistently. NMN and NR reliably increase NAD+ in blood and skeletal muscle in human studies (Martens 2018^[3]; Elhassan 2019^[5]). The pharmacokinetics work.
• Raising NAD+ has not reliably improved energy or fatigue. No adequately powered RCT has demonstrated that NMN or NR supplementation meaningfully reduces subjective fatigue or improves energy in healthy or overweight adults (Dollerup 2018^[4]; Prokopidis 2025^[8]). Some exercise-performance signals exist in older individuals at single doses (Dolopikou 2020^[6]), but this is limited and not the same as treating fatigue.
• IV NAD+ has no controlled energy-outcome evidence at all. The premium IV drip market is built on extrapolation from the oral precursor biology, not on its own RCT evidence for energy or fatigue.
• GLP-1 fatigue has known, addressable causes. Calorie deficit, glycogen depletion, electrolyte losses, and low protein intake drive GLP-1-related fatigue. The evidence-based fixes are protein, hydration, electrolytes, and pacing dose escalation — not NAD+.
• The gap between biomarker and feeling is the key scientific question. The field still needs well-powered, adequately blinded human trials with subjective energy and fatigue as primary endpoints to determine whether the NAD+ biomarker rise translates to a clinically meaningful benefit. That evidence does not yet exist.

This article is educational and is not medical advice. Every claim is sourced to a peer-reviewed study indexed in PubMed and verified against the live PubMed database before publication (2026-07-06). Animal-model findings are labeled as such. No fabricated statistics are used. Discuss any supplement, IV therapy, or medication changes with your prescriber before acting on this information.